immune system
• in all mice at 16 to 20 months of age
|
• splenic CD19+CD5+CD23+ and total CD19+CD5+ cells exhibit proliferation unlike wild-type cells
|
• 4- to 8-fold at 18 months
|
• 4- to 8-fold at 18 months
|
• 4- to 8-fold at 18 months
|
• 4- to 8-fold at 18 months
|
• 4- to 8-fold at 18 months
|
• MCP-1 serum levels are increased 2-fold compared to in wild-type mice
|
• SRBC-injected mice exhibit an 8-fold reduction in serum anti-SRBC antibodies unlike similarly treated wild-type mice
|
neoplasm
• in elderly mice
|
homeostasis/metabolism
• MCP-1 serum levels are increased 2-fold compared to in wild-type mice
|
hematopoietic system
• in all mice at 16 to 20 months of age
|
• splenic CD19+CD5+CD23+ and total CD19+CD5+ cells exhibit proliferation unlike wild-type cells
|
• 4- to 8-fold at 18 months
|
• 4- to 8-fold at 18 months
|
• 4- to 8-fold at 18 months
|
• 4- to 8-fold at 18 months
|
• 4- to 8-fold at 18 months
|
growth/size/body
• in all mice at 16 to 20 months of age
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
chronic lymphocytic leukemia | DOID:1040 |
OMIM:109543 OMIM:151400 OMIM:609630 OMIM:612557 OMIM:612558 OMIM:612559 |
J:160184 |